☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Celltrion
Celltrion’s CT-P39 (biosimilar, omalizumab) Receives the CHMP’s Recommendation for Marketing Authorization to Treat Multiple Indic...
March 25, 2024
Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)
March 11, 2024
Insights+ Key Biosimilars Events of February 2024
March 4, 2024
Celltrion Reports the MAA Submission to the MFDS Korea for CT-P47 (biosimilar, tocilizumab) to Treat Various Indications
February 29, 2024
Celltrion Presents the Long-Term Data for CT-P13 (Biosimilar, Infliximab) to Treat Inflammatory Bowel Disease (IBD) at ECCO 2024
February 23, 2024
Celltrion Reports BLA Submission for CT-P47 (Biosimilar, Actemra) to the US FDA for Treating Rheumatoid Arthritis
January 29, 2024
Load more...
Back to Home